Date:- 18 December, 2018
Tag:- IMMUNOSCORE® in Colon Cancer

  • 9 agreements covering 19 countries signed in 2018
  • Potential of 56 000 Immunoscore® tests annually for early-stage colon cancer patients
  • On track to continue expand this network in 2019 with the goal to serve additional indications of our pipeline

HalioDx, an immuno-oncology company pioneering the immunological diagnosis of cancers, today announced that it has entered into 5 new distribution agreements to cover 15 countries. Distribution agreement are signed with Hyupjin Corporation (South Korea); IDB Resources (Singapore, Malaysia & Thailand); IPS Genomix (Lebanon, Jordan, Kingdom of Saudi Arabia, United Arab Emirates, Egypt, Oman & Qatar); MicroDiagnostics (Greece)and South Genetics (Argentina, Chile & Uruguay) for the promotion and sales of its Immunoscore® assay. This is complementing the 4 distribution agreements already signed earlier this year with Everything Genetic (UK), SOHIN (Mexico),Pronto Diagnostics (Israel) and Gencell Pharma (Colombia). The company is on track to further expand this network in 2019 while supporting its new partners to advocate the introduction of Immunoscore® in the routine practice of oncologists.

These agreements building our distributor network worldwide sign a major milestone as we now cover a geographic area accounting for 56 000 annual new cases of stage II and III colon cancer where Immunoscore® can bring a decisive information to guide treatment options” said Vincent Fert HalioDx CEO. “We are going to further expand this network in 2019 while supporting our new partners to advocate the introduction of Immunoscore® in the routine practice of oncologists, initiallyin Colon Cancer but also in other solid tumor indications in which we are developing Immunoscore®” added Stephane Debono, EVP of the Diagnostics Business Unit at HalioDx.

Immunoscore® Colon was discovered by Dr. Jérôme Galon and developed in compliance with the IVD standards by HalioDx. The clinical value has been validated in several studies on early stage colon cancer patients. Recently the results of the SITC International study* conducted on more than 2600 patients have been published in The Lancet journal. The prognostic value has also been validated on 600 stage III colon cancer patients from the FOLFOX arm of the prospective NCCTG N0147 study**.

* Pagès F, Mlecnik B, Marliot F et al. International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. Lancet. 2018; 391 (10135)
** Sinicrope F, Shi Q, Hermitte F et al. Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). J Clin Oncol. 2018; 36:4s (suppl; abstr 614)



Related Files